Arcturus Therapeutics’ (ARCT) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a report published on Tuesday, Benzinga reports. They currently have a $60.00 price target on the biotechnology company’s stock.

Several other research analysts also recently issued reports on the company. Canaccord Genuity Group lowered their price objective on Arcturus Therapeutics from $87.00 to $86.00 and set a buy rating for the company in a research note on Friday, May 10th. William Blair restated an outperform rating on shares of Arcturus Therapeutics in a report on Thursday, May 23rd. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $64.86.

Arcturus Therapeutics Trading Down 9.2 %

ARCT stock opened at $21.48 on Tuesday. The firm has a 50-day moving average price of $29.99 and a 200-day moving average price of $32.57. Arcturus Therapeutics has a 12 month low of $17.52 and a 12 month high of $45.00. The stock has a market capitalization of $578.46 million, a P/E ratio of -5.49 and a beta of 2.65.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.17) by $0.17. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. The business had revenue of $38.01 million during the quarter, compared to the consensus estimate of $22.12 million. As a group, equities analysts predict that Arcturus Therapeutics will post -4.39 EPS for the current fiscal year.

Insider Activity at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 26,000 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $40.01, for a total transaction of $1,040,260.00. Following the completion of the sale, the chief operating officer now directly owns 447,448 shares in the company, valued at approximately $17,902,394.48. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 13.80% of the stock is owned by company insiders.

Institutional Trading of Arcturus Therapeutics

Large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. bought a new position in Arcturus Therapeutics in the first quarter worth approximately $40,000. AJOVista LLC acquired a new position in Arcturus Therapeutics during the fourth quarter worth $65,000. Quest Partners LLC bought a new stake in shares of Arcturus Therapeutics during the fourth quarter worth about $67,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Arcturus Therapeutics in the 4th quarter worth about $89,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Arcturus Therapeutics by 352.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 2,406 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.